Background Dementia is a common, debilitating feature of late Parkinson's disease (PD). PD
dementia (PDD) is associated with α-synuclein propagation, but coexistent Alzheimer's …

Management of Parkinson's disease (PD) depends primarily on oral medication. There are
several drug classes and multiple doses and formulations, which make optimizing therapy …

Patients take less medication than prescribed in many disease areas but evidence for
suboptimal therapy adherence in Parkinson's disease (PD) is limited. A single‐center …

Background There are currently no treatments that stop or slow the progression of
Parkinson's disease (PD). Case–control genome‐wide association studies have identified …

Two small studies reported suboptimal therapy adherence in Parkinson's disease. We
conducted a larger multicenter European study to assess medicine‐taking behavior …

Objective The purpose of this study was to examine the relationship between vascular
disease (and vascular risk factors), cognition and motor phenotype in Parkinson's disease …

Objectives To use a data-driven approach to determine the existence and natural history of
subtypes of Parkinson's disease (PD) using two large independent cohorts of patients newly …

Background Neuropathological studies, based on small samples, suggest that symptoms of
Parkinson's disease (PD) emerge when dopamine/nigrostriatal loss is around 50–80 …

Objectives To examine the influence of the glucocerebrosidase (GBA) mutation carrier state
on age at onset of Parkinson's disease (PD), the motor phenotype and cognitive function at …

Excessive gambling is recognized with dopamine agonist therapy, but the prevalence is
unknown. We assessed the prevalence of excess gambling by specific prospective enquiry …